|EINECS No.:||200-184-4||Type:||Vitamins, Amino Acids And Coenzymes|
nmn bulk powder,
nmn nicotinamide mononucleotide
Highest quality nad enzyme nicotinamide adenine dinucleotide nad supplement cas 53-84-9
Nicotinamide adenine dinucleotide ( NAD ) is a coenzyme found in all living cells. The compound is a dinucleotide, because it consists of twonucleotides joined through theirphosphate groups. One nucleotide contains an adenine base and the other nicotinamide. Nicotinamide adenine dinucleotide exists in two forms: an oxidized and reduced form abbreviated as NAD+ and NADH respectively.
Nicotinamide adenine dinucleotide has several essential roles in metabolism. It acts as a coenzyme in redox reactions, as a donor of ADP-ribose moieties in ADP-ribosylation reactions, as a precursor of the second messenger molecule cyclic ADP-ribose, as well as acting as a substrate for bacterial DNA ligases and a group of enzymes called sirtuins that use NAD+ to remove acetyl groups from proteins. In addition to these metabolic functions, NAD+ emerges as an adenine nucleotide that can be released from cells spontaneously and by regulated mechanisms, and can therefore have important extracellular roles.
The enzymes that make and use NAD+ and NADH are important in both pharmacology and the research into future treatments for disease. Drug design and drug development exploits NAD+ in three ways: as a direct target of drugs, by designing enzyme inhibitors or activators based on its structure that change the activity of NAD-dependent enzymes, and by trying to inhibit NAD+biosynthesis.
The coenzyme NAD+ is not itself currently used as a treatment for any disease. However, it is being studied for its potential use in the therapy of neurodegenerative diseases such as Alzheimer's and Parkinson disease. Evidence on the benefit of NAD+ in neurodegeneration is mixed; some studies in mice have produced promising results whereas a placebo-controlled clinical trial in humans failed to show any effect.
NAD+ is also a direct target of the drug isoniazid, which is used in the treatment of tuberculosis, an infection caused by Mycobacterium tuberculosis.
|Batch number||ACT20190602||Outer packing||1kg/ Bag|
|Storage||Sealed to keep away from moisture|
|Items of analysis||Specification||Results|
Appearance of solution
(5% w/v in water)
|Colorless and clear||Conforms|
|Yeast and mold||≤100cfu/g||<100|
|Conclusion||Conform with enterprise standard|